A Phase 1b/2 Study of IPI-145 in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia.

Trial Profile

A Phase 1b/2 Study of IPI-145 in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Duvelisib (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Jun 2018 Results presented in the Verastem Oncology media release.
    • 16 Jun 2018 According to a Verastem Oncology media release, data from this trial was presented at the 23rd Congress of the European Hematology Association (EHA) (June 2018).
    • 17 May 2018 According to a Verastem Oncology media release, data from this trial will be presented at the 23rd Congress of the European Hematology Association (EHA) (June 2018).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top